The dataset shows filing peaked at 165 records in 2017 and fell to a 2022 midpoint of 108, well before the latest partial year. This pattern is typical of a field where the core formulation and device claim space — reservoir patches, adhesive matrices, penetration enhancers — was heavily claimed in the 2000s and 2010s, leaving less unclaimed ground for new filers. It does not mean commercial interest has disappeared; it means the easy claim space has largely been taken, and new filings increasingly have to target narrower chemistry or device variants such as dissolving microneedles.

Traditional transdermal patches, which dominate the oldest and most-cited records in this dataset, rely on an adhesive matrix or liquid reservoir to hold drug against the skin for passive diffusion. Dissolving microneedles, reflected in more recent filings such as the representative 2025 record from Dongguk University, use micron-scale needles that physically penetrate the stratum corneum and dissolve to release drug, often combined with stabilising materials like aminoclay to protect biopharmaceuticals. The two approaches sit in different parts of the IPC classification and are increasingly filed by different types of applicant — established pharma for patches, academic and biotech groups for microneedles.

The most-cited single patent in this dataset is a 1990s liquid-reservoir transdermal patch patent for ketorolac, cited far more than any other record, which still functions as a reference point in later filings. ALZA appears repeatedly in the dataset's strongest co-assignee relationships, reflecting a historically central role in transdermal patch technology, though its recent-year filing activity has gone to zero. LTS Lohmann Therapie-Systeme and UCB show the strongest current co-filing relationship in the dataset, pointing to an active device-plus-formulation partnership model.

By IPC volume, device- and electrotherapy-related classes (A61M and A61N) are far smaller than the dominant formulation class (A61K), which suggests device-side and electrically-assisted delivery mechanisms are comparatively under-claimed relative to formulation chemistry. Dissolving microneedle stability and dose-uniformity control in adhesive matrices also show relatively thin claim density given how active they are in recent representative filings. Any white-space assessment should be paired with a freedom-to-operate check against the older, heavily-cited reservoir and matrix-patch patents, since those claims can still constrain new formulation work even in low-density device branches.

The United States and the European Patent Office carry the largest share of receiving-office activity in this dataset, at 1,076 and 711 records respectively, making them the default core markets for competitive filings. WIPO/PCT filings at 500 indicate that international-phase strategy is already standard practice in this field rather than exceptional, and India's 268 records show it is an established secondary market, not a niche one. A filing strategy that only covers the US and Europe risks missing meaningful prior art and competitive activity already established through the PCT and Indian filing routes.